Gulbrandsen Technologies is proud to announce its participation in the DCVMN Annual General Meeting 2025. This prestigious global gathering brings together vaccine manufacturers, researchers, and innovators dedicated to improving global immunization access and quality. You can meet our team at Booth B7, where we will be showcasing our vaccine adjuvants developed under our Life Sciences…

In the global effort to protect populations against infectious diseases, vaccines play a central role. But behind every effective vaccine is a complex formulation designed to elicit a strong and lasting immune response. One of the most critical components in this formulation is the vaccine adjuvant—an ingredient that enhances the body’s immune response to the…

Gastrointestinal (GI) disorders continue to affect millions of people worldwide, driving the demand for safe, effective, and well-tolerated treatments. Among the widely prescribed therapies for ulcers and related conditions is Sucralfate—a proven anti-ulcerant known for its protective action on the gastrointestinal lining. At Gulbrandsen Technologies, we play a vital role in ensuring global access to…

Gulbrandsen Technologies is currently building a new facility for the production of aluminum-based adjuvants at its current site in Gujarat, India – strictly compliant with cGMP regulations for the manufacture of sterile vaccine adjuvants, targeting both human and veterinary applications. According to company president, Vikram Singhal, Gulbrandsen Technologies has been making the world a better…